More News

16 Oct 2018 Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
11 Oct 2018 Themis Bioscience Announces Exclusive Licensing Agreement with Max-Planck-Innovation to Develop and Commercialize Oncolytic Virotherapies
11 Oct 2018 Debiopharm International SA and the Paul Scherrer Institute Announce a Licensing Agreement for the Development of a Novel Targeted Radiotherapeutic Product in Oncology
11 Oct 2018 Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman
10 Oct 2018 Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases
10 Oct 2018 MeiraGTx Announces Acquisition of Vector Neurosciences, Gains Phase 2 Gene Therapy Program for Parkinson’s Disease
10 Oct 2018 Mundipharma Strengthens Position as a Leader in Biosimilars with Acquisition of Development Company Cinfa Biotech
10 Oct 2018 Therachon Expands Rare Disease Pipeline with Acquisition of GLyPharma Therapeutic Inc.
10 Oct 2018 Biohaven Acquires Option To License Biologic Investigational Agent For Inflammatory And Autoimmune Diseases From The University of Connecticut
10 Oct 2018 Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders
09 Oct 2018 Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
09 Oct 2018 Ziopharm and Precigen Redefine Relationships, Announce New License Agreement
06 Oct 2018 Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscular Disorder
06 Oct 2018 Evotec Signs Agreement With Sanofi To Advance Early Stage Academic Research Into Novel Therapeutic Candidates
05 Oct 2018 Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies
04 Oct 2018 Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection
04 Oct 2018 Cellular Biomedicine Group Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology to Treat Solid Tumors
04 Oct 2018 Boston Pharmaceuticals Adds Five New Drug Programs to Its Pipeline in Licensing Deal
03 Oct 2018 Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
02 Oct 2018 Kite and HiFiBiO Therapeutics Announce a Research Collaboration to Develop Technology for the Potential Discovery of Neoantigen-Reactive T Cell Receptors (TCRs) for the Treatment of Cancer
02 Oct 2018 GO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment
02 Oct 2018 AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives
02 Oct 2018 Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors
28 Sep 2018 Tusk Therapeutics to be acquired by Roche
27 Sep 2018 Decibel Therapeutics and Oricula Therapeutics Announce Exclusive License for ORC-13661 in Phase 1 Development for Hearing and Balance Protection

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up